S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
Nov 16, 2023
13:07
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.
OncLive® On Air